Inovio Pharmaceuticals (INO) closed at $1.89 on November 2, 2026, up 214.0% from the previous close, on volume of 162,562,239 shares (30-day average 6,303,608).
Data as of November 2, 2026.
INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026
PRNewswire (Mon, 2-Nov 4:15 PM ET)
INOVIO to Participate in Upcoming Scientific Conferences
PRNewswire (Mon, 2-Nov 4:01 PM ET)
3 Penny Stocks to Watch Today, November 2
TipRanks (Mon, 2-Nov 2:25 PM ET)
Precigen craters on Inovio Voceryq immunotherapy approval
Seeking Alpha News (Mon, 2-Nov 11:14 AM ET)
INOVIO Upgraded to Buy as FDA Approves VOCERYQ and Price Target Doubles to $5
TipRanks (Mon, 2-Nov 10:36 AM ET)
Piper Sandler Sticks to Their Buy Rating for Inovio Pharmaceuticals (INO)
TipRanks (Mon, 2-Nov 10:28 AM ET)
Biggest stock movers Monday: KOS, INO, LITE, AMZN, and more
Seeking Alpha News (Mon, 2-Nov 10:09 AM ET)
Market Chameleon (Mon, 2-Nov 4:52 AM ET)
Why Is Penny Stock Inovio Pharmaceuticals (INO) Up 243% Today?
TipRanks (Mon, 2-Nov 9:31 AM ET)
Inovio Pharmaceuticals Receives FDA Approval for VOCERYQ
TipRanks (Mon, 2-Nov 8:01 AM ET)
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Inovio Pharmaceuticals trades on the NASDAQ stock market under the symbol INO.
As of November 3, 2026, INO stock price climbed to $1.99 with 16,915,012 million shares trading.
INO has a beta of 1.99, meaning it tends to be more sensitive to market movements. INO has a correlation of 0.05 to the broad based SPY ETF.
INO has a market cap of $205.62 million. This is considered a Small Cap stock.
Last quarter Inovio Pharmaceuticals reported $0 in Revenue and -$.07 earnings per share. This fell short of revenue expectation by $-400,000 and exceeded earnings estimates by $.18.
In the last 3 years, INO traded as high as $14.75 and as low as $.56.
The top ETF exchange traded funds that INO belongs to (by Net Assets): VTI, VXF, QQQS, IWC.
INO has underperformed the market in the last year with a return of -15.3%, while SPY returned +11.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in INO shares. However, INO has outperformed the market in the last 3 month and 2 week periods, returning +193.9% and +99.0%, while SPY returned +1.2% and -1.6%, respectively. This indicates INO has been having a stronger performance recently.
INO support price is $1.74 and resistance is $2.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INO shares will trade within this expected range on the day.
